Transforming growth factor β, (TGFβ) secreted by immunogenic ex vivo human carcinoma cells, counteracts the activation and inhibits the function of autologous cytotoxic lymphocytes. Pretreatment with interferon γ and tumor necrosis factor α reduces the production of active TGFβ

Cancer Immunology Immunotherapy

Volumn 45, Issue 6, 1998, Pages 306-312

  Nagy, Noémi ^a,b   Vánky, Farkas ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cytotoxic lymphocytes; Human carcinoma; Interferon ; Transforming growth factor ; Tumor necrosis factor

Indexed keywords

GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CARCINOMA CELL; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOREACTIVITY; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNOLOGY;

EID: 0031910618     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050447     Document Type: Article

References (39)

1. Arany I, Rady P, Tyring FK (1994) Interferon treatment enhances the expression of underphosphorylated (biologically-active) retinoblastoma protein in human papilloma virus-infected cells through the inhibitory TGFβ1/IFNβ cytokine pathway. Antiviral Res 23:131-141
2. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM Forbes JT (1993) Anti-transforming growth factor (TGF)-β antibodies inhibit breast carcinoma tumorigenicity and increase mouse spleen natural killer cell activity. J Clin Invest 92:2569-2576
3. Bodmer S, Srommer K, Frei K, Siepl C, Tribolet N de, Heid I, Fontana A (1989) Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β2. J Immunol 143:3222-3229
4. Brown PD, Wackefield LM, Lewinson AD, Sporn MB (1990) Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3. Growth Factors 3:35-44
5. Bøyum A (1974) Separation of blood leukocytes, granulocytes and lymphocytes. Tissue Antigens 4:269-274
6. Cone JL, Brown DR, DeLarco JL (1988) An improved method of purification of transforming growth factor, type β, from platelets. Anal Biochem 168:71-74
7. Dennis PA, Rifkin DB (1991) Cellular activation of latent transforming growth factor b requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci USA 88:580-584
8. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman DS, Berger WH (1987) Synthesis of messenger RNAs for transforming growth factor alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 47:707-712
9. Game SM, Huelsen A, Patel V, Donelly M, Yuedall WA, Stone A, Fusenig NE, Prime SS (1992) Progressive abrogation of TGFβ and EGF growth control is associated with tumor progression in ras-transfected human keratinocytes. Int J Cancer 52:461-470
10. Higgins K A, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA, Narayanan R (1993) Antisense inhibition of the p65 subunit of NF-κ B blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci USA 90:9901-9905
11. Huber D, Fontana A, Bodmer S (1991) Activation of human platelet-derived latent transforming growth factor-β1 by human globlastoma cells. Biochem J 277:165-173
12. Julius MH, Simpson E, Herzenberg LA (1973) Rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol 3:645-649
13. Kadin ME, Cavaille-Coll MW, Gertz R, Massagué J, Heifetz S, George D (1994) Loss of receptors for transforming growth factor β in human T-cell malignances. Proc Natl Acad Sci USA 91:6002-6006
14. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn M, Fauci AM (1986) Production of transforming growth factor-β by human T lymphocytes and its potential role in the regulation of T-cell growth. J Exp Med 163:1037-1050
15. Klein E, Vánky F, Galili U, Vose B, Fopp M (1980) Separation and characteristics of tumor-infiltrating lymphocytes in man. In: Witz IP, Hanna MG Jr (eds) Contemporary topics in immunobiology, vol 10. Plenum, New York, pp 79-107
16. Lahio M, Weis FMB, Boyd FT, Ignotz RA, Massagué J (1991) Responsiveness to transforming growth factor-β (TGFβ) restored by genetic complementation between cells defective in TGFβ receptors I and II. J Biol Chem 266:9108-9112
17. Lahm H, Odartchenko N (1992) Role of tarnsforming growth factor-b in colorectal cancer. Growth Factors 9:1-9
18. Li X-F, Takiuchi H, Zou J-P, Katagiri T, Yamamoto N, Nagata T, Ono S, Fujiwara H, Hamaoka T (1993) Transforming growth factor-β (TGF-β)-mediated immunosuppression in the tumour-bearing state: Enhanced production of TGF-β and progressiv increase in TGF-β susceptibility of anti-tumour CD4+ T cell function. Jpn J Cancer Res 84:315-325
19. cdc2 regulation in ras-transfected epithelial cells. Oncogene 7:1549-1556
20. Lucas C, Bald L N, Fendly BM, Mora-Worms M, Figari IS, Patzer EJ, Palladino MA, (1990) The autocrine production of transforming growth factor-β1 during lymphocyte activation. A study with monoclonal antibody-based ELISA. J Immunol 145:1415-1422
21. Massagué J, Cheifetz S, Laiho M, Ralph DA, Wies FMB, Zentella A (1992) Transforming growth factor-β. Cancer Surv 12:81-103
22. Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, Fliedner V von (1988) Proliferative and cytotoxic potentials of purified human tumor infiltrating T lymphocytes. Impaired response to mitogen driven stimulation despite T-cell receptor expression. Int J Cancer 42:659-666
23. Miescher S, Whiteside TL, Carrel S, Fliender V von (1986) Functional properties of tumor-infiltrating lymphocytes and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136:1899-1907
24. Miotti S, Canevari S, Ménard S, Mezzanzanica D, Porro G, Pupa S, Regazzoni M, Tagliabue E, Colnaghi M (1987) Characterization of human ovarian-associated antigens defined by novel monoclonal antibodies with tumor restrictive specificity. Int J Cancer 39:297-303
25. Nilsson BS (1972) The response of lymphocytes from tuberculin positive and negative humans to various doses of PPD-tuberculin in vitro. Cell Immunol 3:493-500
26. Rodeck U, Bossler A, Graeven U, Fox FE, Nowell PC, Knabbe K, Kari C (1994) Transforming growth factor-β production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 54:575-581
27. Rosenberg GL, Farber PA, Notkins AL (1972) In vitro stimulation of sensitized lymphocytes by herpes simplex virus and vaccinia virus. Proc Natl Acad Sci USA 69:756-760
28. Ruscetti FW, Palladino MA (1991) Transforming growth factor-β and the immune system. Prog Growth Factor Res 3:159-175
29. Sahin U, Türeci Ö, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreunschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92:11810-11813
30. Schwarz LC, Gingras M-C, Goldberg G, Greenberg AH, Wright JA, (1988) Loss of growth factor dependence and conversion of transforming growth factor-β1 inhibition to stimulation in metastatic H-ras-transformed murine fibroblasts. Cancer Res 48:6999-7003
31. Sulitzeanu D (1993) Immunosuppressive factors in human cancer. Adv Cancer Res 60:247-267
32. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL., Rowley DA (1990) A highly immunogenic tumor transfected with murine transforming growth factor β-1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87:1486-1490
33. Vánky F, Klein E (1991) Requirement of MHC class I antigen expression on human solid tumors for in vitro recognition by autologous blood lymphocytes. Sem Cancer Biol 2:55-62
34. Vánky F, Klein E, Stjernswärd J, Nilsonne U (1974) Cellular immunity against tumor associated antigens in humans: lymphocyte stimulation and skin reaction. Int J Cancer 14:277-288
35. Vánky F, Klein E, Willems J, Böök K, Ivert T, Péterffy A (1987) Recognition of autologous tumor cells by blood lymphocytes in patients with lung cancer. In: Byers VS, Baldwin RW (eds) Immunology of malignant diseases. MTP, London, pp 105-127
36. Vánky F, Nagy N, Hising C, Sjövall K, Larson B, Klein E (1997) Human ex vivo carcinoma cells produce transforming growth factor β and thereby can inhibit lymphocyte functions in vitro. Cancer Immunol Immunother 43:317-323
37. Vose BM, Vánky F, Klein E (1977) Human tumor-lymphocyte interaction in-vitro. V. Comparison of the reactivity of tumor infiltrating, blood and lymph node lymphocytes with autologous tumor cells. Int J Cancer 20:895-902
38. Wahl SM, McCartney-Francis N, Allen JB, Dougherty EB, Dougherty SF (1990) Macrophage production of TGF-β and regulation by TGF-β. Ann NY Acad Sci 593:188-196
39. Wilson DB (1968) Quantitative studies on the mixed lymphocyte interactions in rats. I. Conditions and parameters of response. J Exp Med 126:625-654